Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in GoPro, Inc. of Class Action Lawsuit and Upcoming Deadline – GPRO

NEW YORK, Nov. 25, 2016 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against GoPro, Inc. (“GoPro” or the “Company”)(NASDAQ: GPRO) and certain of its officers. The class action, filed in United States District Court, Northern District of California, and docketed under 16-cv-06654, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired GoPro between September 19, 2016 and November 4, 2016, both dates inclusive (the “Class Period”), seeking to recover compensable damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased GoPro during the Class Period, you have until January 17, 2017 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

[Click here to join this class action]

GoPro develops and sells mountable and wearable cameras and accessories in the United States and internationally. The Company’s cameras are designed primarily for filming while immersed in action, such as outdoor or extreme sports. On October 23, 2016, following months of delays, GoPro released the Karma drone, a compact, foldable drone designed for aerial photography using GoPro’s cameras.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) GoPro’s Karma drones were prone to losing power midflight, causing them to fall out of the sky; (ii) the Company had thus significantly overstated the utility of and likely customer demand for the Karma drone; (iii) the foregoing issue, when publicly known, would necessitate a costly recall of the Company’s Karma drones; and (iv) as a result, GoPro’s public statements were materially false and misleading at all relevant times.

On November 3, 2016, shortly before the market closed, GoPro issued a press release and filed a Current Report on Form 8-K with the SEC announcing the Company’s financial and operating results for the quarter ended September 30, 2016 (the “Q3 2016 8-K”). Among other information, the Q3 2016 8-K provided revenue guidance for 2016 in the range of $1.25 billion and $1.3 billion–a significant decrease from the revenue guidance of $1.35 billion and $1.5 billion that the Company had provided in reporting its financial and operating results for the previous quarter, and consistent with an anticipated recall of the Company’s Karma drone.

On this news, GoPro’s share price fell $0.90, or 7.01%, to close at $11.94 on November 3, 2016, and fell an additional $0.78, or 6.53%, to close at $11.16 on November 4, 2016.

On November 8, 2016, post-market, GoPro announced the recall of the approximately 2,500 Karma drones purchased by consumers since the product’s release, advising that the Company had discovered that Karma units were prone to losing power during operation.

On this news, GoPro’s share price fell $0.45, or 4.14%, to close at $10.41 on November 9, 2016.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-gopro-inc-of-class-action-lawsuit-and-upcoming-deadline–gpro-300368230.html

SOURCE Pomerantz LLP


Go to Source

Big plans ahead for law firm Quinn Legal

Quinn Legal has appointed Stephen Savage as head of the Corporate and Commercial legal team.

Stephen, a Manx advocate and qualified Scottish and English solicitor, said of his appointment: ‘I am delighted to be joining.

‘Quinn Legal is a leading Isle of Man law firm and separates itself from other law firms by offering an approachable style in its provision of legal services on the Island.

‘I am looking forward to working with the team to further develop the client experience and expand the services offered.’

Quinn Legal is based in Ridgeway Street, Douglas, and provides an expansive range of legal services to individuals and businesses in the island.

The firm’s business team supports local companies and corporate service providers with specialist services across banking and finance, commercial, commercial litigation, corporate, regulatory investigation, data protection, digital currency, criminal and employment law.

Managing director James Quinn said: ‘Our approachable business team is a dedicated and reliable resource for local businesses and corporate service providers.

‘We’re absolutely thrilled to welcome Stephen to the team and look forward to working with him.

‘Stephen has joined Quinn Legal at a very exciting time. This year we’ve rebranded, launched a new website and have many big plans in the bag for 2017.’

Stephen’s commercial legal experience is extensive.

He is a Manx Advocate (admitted 2012) and qualified Scottish and English Solicitor (1994 and 2000 respectively).

Having worked in the Isle of Man and in other jurisdictions such as the Caribbean,

Stephen brings insight and valuable knowledge of corporate and commercial law on an international 
scale.

Go to Source

Law firm growth is ahead of target

BUSINESS growth at a West Yorkshire law firm is running at 30 per cent above target following a change of ownership earlier this year.

Jeremy Garside, Robert Brackup and Tim Welton assumed control of Cleckheaton-based Williams & Co Solicitors in February and following recent growth are looking to increase turnover to £2 million within the next 12 months.

Following their takeover, the trio of partners have focused on expanding its work in residential property, commercial and corporate, specialist litigation and probate.

Rising demand from new and existing clients has led to several staff appointments since the new owners took control, taking the workforce to 26.

Three more staff have just been hired and the owners plan more recruitment in the next three to six months which would take the firm to twice its original size.

Jeremy Garside said: “It was our ambition to strengthen and build the team at Williams & Co quickly but even we are impressed by the speed at which we have managed to grow the firm. This is down to the talented individuals who aim to deliver high quality services in language that clients understand to produce the results they are looking for. It has been an exciting year so far and we are now looking forward to an even more exciting 2017.”

Jonathan Perry, Cassie Land and Danielle Burrow are the latest recruits at Williams & Co Solicitors, which also has a Wakefield office and specialises in commercial and civil litigation, regulatory defence, commercial property and conveyancing.

Jonathan Perry has joined as an associate solicitor in charge of expanding the commercial property side of the business in Wakefield and to mentor other fee earners including, associate legal executive,Cassie.

He has worked in leading commercial law firms in London and Leeds as well as in-house at both Shepherd Building Group and for Barnsley Council.

Cassie has joined from Leeds-based DWF LLP to work in the residential team.

Newly-qualified solicitor Danielle Burrow will work in the dispute resolution team having worked in the legal profession for five years.

Meanwhile, Bradford-based law firm Schofield Sweeney has hired 13 new staff since July.

The latest four recruits are legal executive Kate Fox who has joined the corporate team; solicitor Paul Cantwell in the dispute resolution team and associates Jennifer Clarke, in the education and projects team and Zoe Oates in the restructuring and insolvency team.

The firm, which merged with Huddersfield based Armitage Sykes earlier this year, now employs more than 150 staff across three sites.

Go to Source

Lundin Law PC Announces Securities Class Action Lawsuit against Xerox Corporation and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 25, 2016 / Lundin Law PC, a shareholder rights firms, announces a class action against Xerox Corporation (“Xerox” or the “Company”) (NYSE: XRX) concerning possible violations of federal securities laws. Investors who purchased or otherwise acquired Xerox shares between April 23, 2012 and October 23, 2015 (the “Class Period”), are reminded to contact the firm before the December 23, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, Xerox repeatedly touted its new software product, Health Enterprise, as an important growth area for the Company, which would operate at low cost and high profit margin. Xerox’s statements pertaining to the profitability and growth prospects of the Health Enterprise business were materially false and misleading because Xerox failed to disclose: that the Company’s existing Health Enterprise projects were experiencing major delays and cost overruns; that Xerox would be unable to deliver Health Enterprise implementations at sustainable profits; and that as a result of the above, the Company’s statements about its business, operations, and prospects lacked a reasonable basis.

On October 26, 2015, Xerox released its third quarter 2015 financial results which were disappointing due to costs associated with the implementation of Health Enterprise and the termination of Health Enterprise contracts with two state agencies. When this news was disclosed, shares of Xerox fell in value, causing investors harm.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com

http://lundinlawpc.com/

SOURCE: Lundin Law PC


Go to Source

SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Xerox Corporation and Reminds Investors with Losses to Contact the Firm

Nov 25, 2016 (ACCESSWIRE via COMTEX) — LOS ANGELES, CA / ACCESSWIRE / November 25, 2016 / Lundin Law PC, a shareholder rights firms, announces a class action against Xerox Corporation (“Xerox” or the “Company”)












XRX, +1.19%










concerning possible violations of federal securities laws. Investors who purchased or otherwise acquired Xerox shares between April 23, 2012 and October 23, 2015 (the “Class Period”), are reminded to contact the firm before the December 23, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, Xerox repeatedly touted its new software product, Health Enterprise, as an important growth area for the Company, which would operate at low cost and high profit margin. Xerox’s statements pertaining to the profitability and growth prospects of the Health Enterprise business were materially false and misleading because Xerox failed to disclose: that the Company’s existing Health Enterprise projects were experiencing major delays and cost overruns; that Xerox would be unable to deliver Health Enterprise implementations at sustainable profits; and that as a result of the above, the Company’s statements about its business, operations, and prospects lacked a reasonable basis.

On October 26, 2015, Xerox released its third quarter 2015 financial results which were disappointing due to costs associated with the implementation of Health Enterprise and the termination of Health Enterprise contracts with two state agencies. When this news was disclosed, shares of Xerox fell in value, causing investors harm.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com

http://lundinlawpc.com/

SOURCE: Lundin Law PC

http://www.accesswire.com/img.ashx?id=449751

Copyright 2016 ACCESSWIRE



















Go to Source

Xerox Corp : Lundin Law PC Announces Securities Class Action Lawsuit against Xerox Corporation and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 25, 2016 / Lundin Law PC, a shareholder rights firms, announces a class action against Xerox Corporation (“Xerox” or the “Company”) (NYSE: XRX) concerning possible violations of federal securities laws. Investors who purchased or otherwise acquired Xerox shares between April 23, 2012 and October 23, 2015 (the “Class Period”), are reminded to contact the firm before the December 23, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, Xerox repeatedly touted its new software product, Health Enterprise, as an important growth area for the Company, which would operate at low cost and high profit margin. Xerox’s statements pertaining to the profitability and growth prospects of the Health Enterprise business were materially false and misleading because Xerox failed to disclose: that the Company’s existing Health Enterprise projects were experiencing major delays and cost overruns; that Xerox would be unable to deliver Health Enterprise implementations at sustainable profits; and that as a result of the above, the Company’s statements about its business, operations, and prospects lacked a reasonable basis.

On October 26, 2015, Xerox released its third quarter 2015 financial results which were disappointing due to costs associated with the implementation of Health Enterprise and the termination of Health Enterprise contracts with two state agencies. When this news was disclosed, shares of Xerox fell in value, causing investors harm.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com

http://lundinlawpc.com/

SOURCE: Lundin Law PC


Go to Source

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Teva Pharmaceutical Industries Ltd. of Class Action Lawsuit and Upcoming Deadline – TEVA

NEW YORK, Nov 26, 2016 (GLOBE NEWSWIRE via COMTEX) —

Pomerantz LLP announces that a class action lawsuit has been filed against Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”)












TEVA, +0.26%










and certain of its officers.   The class action, filed in United States District Court, Southern District of New York, and docketed under 16-cv-08747, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Teva securities between February 10, 2014 and November 2, 2016, both dates inclusive (the “Class Period”), seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased Teva securities during the Class Period, you have until January 5, 2017 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased. 

[Click here to join this class action]

Teva develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide.  Teva is the largest generic drug manufacturer in the world and one of the 15 largest pharmaceutical companies worldwide.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:  (i) Teva and several of its pharmaceutical industry peers colluded to fix generic drug prices; (ii) the foregoing conduct constituted a violation of federal antitrust laws; (iii) consequently, Teva’s revenues during the Class Period were in part the result of illegal conduct; and (iv) as a result of the foregoing, Teva’s public statements were materially false and misleading at all relevant times. 

On November 3, 2016, media outlets reported that U.S. prosecutors might file criminal charges by the end of 2016 against Teva and several other pharmaceutical companies for unlawfully colluding to fix generic drug prices.

On this news, Teva’s ADR price fell $4.13, or 9.53%, to close at $39.20 on November 3, 2016.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

 CONTACT: Robert S. Willoughby Pomerantz LLP rswilloughby@pomlaw.com 

Copyright (C) 2016 GlobeNewswire, Inc. All rights reserved.



















Go to Source

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investments in Impax Laboratories Inc. of Class Action Lawsuit and Upcoming Deadline – IPXL

NEW YORK, Nov 26, 2016 (GLOBE NEWSWIRE via COMTEX) —

Pomerantz LLP announces that a class action lawsuit has been filed against Impax Laboratories Inc. (“Impax” or the “Company”)












IPXL, +4.50%










and certain of its officers.  The class action, filed in United States District Court, Northern District of California, and docketed under 16-cv-06557, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Impax securities between February 20, 2014 and November 2, 2016, both dates inclusive (the “Class Period”), seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased Impax securities during the Class Period, you have until January 9, 2017 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.  To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased. 

[Click here to join this class action]

Impax, a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products.  Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals Curacao N.V. to develop, manufacture, and distribute controlled release generic pharmaceutical products.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:  (i) Impax and several of its pharmaceutical industry peers colluded to fix generic drug prices; (ii) the foregoing conduct constituted a violation of U.S. antitrust laws; (iii) consequently, Impax’s revenues during the Class Period were in part the result of illegal conduct; and (iv) as a result of the foregoing, Impax’s public statements were materially false and misleading at all relevant times. 

On November 3, 2016, media outlets reported that U.S. prosecutors might file criminal charges by the end of 2016 against Impax and several other pharmaceutical companies for unlawfully colluding to fix generic drug prices. 

On this news, Impax’s share price fell $4.00, or 19.51%, to close at $16.50 on November 3, 2016.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

 CONTACT: Robert S. Willoughby Pomerantz LLP rswilloughby@pomlaw.com 

Copyright (C) 2016 GlobeNewswire, Inc. All rights reserved.



















Go to Source

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alexion Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – ALXN



NEW YORK, Nov. 25, 2016 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Alexion Pharmaceuticals, Inc. (“Alexion” or the “Company”)












ALXN, -0.08%










and certain of its officers.  The class action, filed in United States District Court, Southern District of New York, and docketed under 16-cv-08946, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Alexion between February 10, 2014 and November 9, 2016, both dates inclusive (the “Class Period”), seeking to recover compensable damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased Alexion during the Class Period, you have until January 17, 2017 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.  To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased. 

[Click here to join this class action]

Alexion, a biopharmaceutical company, develops and commercializes therapeutic products. Among the Company’s products is Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder, and atypical hemolytic uremic syndrome (aHUS), a genetic disease.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Alexion employed improper sales practices with respect to Soliris; (ii) consequently, the Company’s revenues from Soliris sales were unlikely to be sustainable; and (iii) as a result of the foregoing, Alexion’s public statements were materially false and misleading at all relevant times. 

On November 4, 2016, Alexion cancelled an appearance at the Credit Suisse Healthcare Conference, scheduled for November 6-8, 2016, telling Leerink Partners LLC only that “something came up.”  Following the cancellation, analysts noted that Alexion had also failed to file its Quarterly Report on Form 10-Q with the SEC within two days of its earnings announcement on October 27, 2016, a break from the Company’s historical practice.

On this news, Alexion’s share price fell $8.95, or 6.94%, to close at $120.05 on November 7, 2016, the following trading day.

On November 9, 2016, post-market, Alexion issued a press release and filed a Current Report on Form 8-K with the SEC concerning certain of the Company’s financial and operating results for the quarter ended September 30, 2016 (the “Q3 2016 8-K”) and filed a Form NT 10-Q with the SEC (the “Q3 2016 NT 10-Q”), announcing that the Company would not be able to timely file its financial and operating results for the quarter ended September 30, 2016.

On this news, Alexion’s share price fell $0.28, or 0.22%, to close at $126.88 on November 10, 2016.  As the market continued to digest the significance of Alexion’s announced investigation, Alexion’s share price fell an additional $13.26, or 10.45%, to close at $113.62 on November 11, 2016.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert–pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-alexion-pharmaceuticals-inc-of-class-action-lawsuit-and-upcoming-deadline–alxn-300368225.html

SOURCE Pomerantz LLP

Copyright (C) 2016 PR Newswire. All rights reserved



















Go to Source